BioWorld

Feb. 16, 2005

Aphton's Insegia Misses In Pancreatic Cancer Phase III

Aphton Corp.'s stock fell more than 45 percent Tuesday following news that its lead pancreatic cancer drug, Insegia, failed to meet the primary endpoint in a Phase III trial. (BioWorld Today) Read More

Vertex, Avalon Sign $73M Cancer Drug Agreement

Kinase Inhibitor Profiling Method Gives New Therapeutic Insights

Crawford Receives Bush's Nomination As FDA Head

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for Feb. 9, 2025.

MJFF grant supports Bexorg’s translational biomarker work

BioWorld Science

Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...

Illustration of SCAN in Parkinson’s vs healthy subcortex

SCAN is core circuit affected in Parkinson’s disease

BioWorld Science

Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...

Astellas’ ASP-2246 shows promise in stroke management

BioWorld Science

Astellas Pharma Inc. recently presented data regarding ASP-2246, a drug candidate comprised of an mRNA encoding the transcription factor NeuroD1 encapsulated in...

News in brief

BioWorld Asia

BioWorld Asia briefs for Feb. 3, 2026